Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol. 2010; 17 (4):1168–1176.Siddiqui AD, Piperdi B.. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 2010; 17 :1168-76....
27,28. EachKRASmutation allele subtype has unique biochemical and clinicopathological features, and the differences between the mutation subtypes and co-mutations in pancreatic cancer have not been well studied26,27,28,29. TheKRASG12Dmutation has an intrinsic wildtype and SOS1 guanine exchange...
近日,《肿瘤学年鉴》(Annals Of Oncology)发表了题为:Different prognostic values ofKRASexon 2 submutations andBRAF V600Emutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDE...
Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value The purpose of this study was to examine the prognostic and oxaliplatin predictive value of mismatch repair (MMR) status and common hot spot mutations,...
In particular, approximately 30%–40% of colon cancers harbor aKRASmutation.KRASmutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally,KRASmutations in colorectal cancer lead to resistance to select treatment strategies. In this review we ...
Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primaryLETTERS to the editorCOLON cancerTUMORSThe BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new ...
COLON cancerETHNIC groupsThe article comments on the results of the study by A. Syed et al on the role of mutations of KRAS oncogene and TP53 gene in colorectal carcinoma (CRC) in Kashmiri population from India published in the same issue. The study found that the incidence of KRAS ...
5]Prior I.A. Hood F.E.HartleyJ.L. The frequency ofRasmutations in cancer[J] . Cancer Res...
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900... LB Saltz,RJ Mayer,P Schaefer,... - 《Clinical Cancer Research》 被引量: 393发表: 2012年 KRAS Mutation in Stage III Colon Cancer and...
KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann. Surg. Oncol. 17, 1168–1176 (2010). Article PubMed Google Scholar Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532–536 (2012...